ABCL
AbCellera Biologics Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $2.68 | $4.16 | +55% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $2.62 | $4.16 | +59% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $2.62 | $4.16 | +59% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $2.62 | $4.16 | +59% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $3.17 | $4.16 | +31% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| D.E. Shaw 2× in & out | Q3 2025 | Q2 2026 | → $4.09 | -9% |
| Duquesne Family Office 2× in & out | Q4 2021 | Q2 2024 | — | +0% |
| Maverick Capital | Q4 2022 | Q4 2023 | → $4.33 | -70% |
| Viking Global Investors | Q1 2021 | Q3 2021 | → $18 | -60% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at AbCellera Biologics Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 3, 2026 — the most recent Form 4 on file — not from today.
- Form 40001834411-26-000006Jun 3, 2026
- Form 40001834423-26-000004May 18, 2026
- Form 40001834449-26-000004Mar 2, 2026
- Form 40001834449-26-000002Feb 27, 2026
- Form 40001834411-26-000004Feb 27, 2026
- Form 40001834411-26-000002Jan 5, 2026
- Form 40001834412-26-000002Jan 5, 2026
- Form 40001834424-26-000002Jan 5, 2026
- Form 40001834418-26-000002Jan 5, 2026
- Form 40001685889-25-000008Dec 19, 2025
- Form 40001834449-25-000004Dec 19, 2025
- Form 40001834423-25-000004Nov 26, 2025
- Form 40001628280-25-033735Jul 1, 2025
- Form 40001628280-25-031647Jun 16, 2025
- Form 40001628280-25-031646Jun 16, 2025
Fundamentals
XBRL · AbCellera Biologics Inc.Annual figures sourced directly from AbCellera Biologics Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for AbCellera Biologics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 5, 2026
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 11, 2026
- DEF 14AProxy statementApr 29, 2026
- 10-KAnnual reportFeb 24, 2026
- 8-KMaterial eventFeb 24, 2026
- 8-KMaterial eventJan 14, 2026
- 8-KMaterial eventDec 18, 2025
- 8-KMaterial eventNov 28, 2025
- 8-KMaterial eventNov 12, 2025
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventSep 10, 2025
- 10-QQuarterly reportAug 7, 2025
- 8-KMaterial eventAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $3.17 | $4.16 | +31% |
| D.E. Shaw | Q3 2025 | Q2 2026 | $4.50 | $4.09 | -9% |
| Citadel Advisors | Q3 2024 | open | $2.62 | $4.16 | +59% |
| Two Sigma Investments | Q3 2024 | open | $2.62 | $4.16 | +59% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $2.62 | $3.27 | +25% |
| Millennium Management | Q3 2024 | open | $2.62 | $4.16 | +59% |
| Renaissance Technologies | Q3 2024 | open | $2.68 | $4.16 | +55% |
| Maverick Capital | Q4 2022 | Q4 2023 | $14 | $4.33 | -70% |
| Duquesne Family Office | Q4 2021 | Q2 2024 | $0.00 | — | +0% |
| Viking Global Investors | Q1 2021 | Q3 2021 | $44 | $18 | -60% |
| Duquesne Family Office | Q1 2021 | Q3 2021 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.